The MISCAN-Fadia Continuous Tumor Growth Model for Breast Cancer

Published in: Journal of the National Cancer Institute Monographs, v. 36, Chapter 9, 2006, p. 56-65

Posted on RAND.org on January 01, 2006

by Sita Y G L Tan, Gerritt J van Oortmarssen, Harry J. de Koning, Rob Boer, John Dik F Habbema

Read More

Access further information on this document at jncimono.oxfordjournals.org

This article was published outside of RAND. The full text of the article can be found at the link above.

The MISCAN-Fadia model was used to analyze the impact of screening and adjuvant treatment on U.S. breast cancer mortality between 1975 and 2000. MISCAN-Fadia uses the concept of fatal diameter to model survival and screening benefit and is based on continuous tumor growth. It consists of four major components: population, natural history, screening, and treatment. Population parameters were quantified using U.S. population data. Most natural history and screening parameters were fitted to the Swedish Two County screening trial data; some were based on Surveillance, Epidemiology, and End Results data. Adjuvant treatment parameters were quantified using data from the Early Breast Cancer Trialists' Collaborative Group's meta-analysis. The simulated trend in incidence matches the observed trend reasonably well; the simulated mortality is equal to the observed in 1975 but becomes increasingly too high in 2000. The authors estimate that screening leads to a 15% and adjuvant treatment to a 21% mortality reduction in the year 2000.

This report is part of the RAND Corporation external publication series. Many RAND studies are published in peer-reviewed scholarly journals, as chapters in commercial books, or as documents published by other organizations.

The RAND Corporation is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.